



UDC 616.34-002:005

**SILVIO DANESE**

*Humanitas University, Milan, Italy*

### MODERN TREATMENT IN IBD MANAGEMENT

**I**nflammatory bowel diseases (IBD) present a typically relapsing-remitting behavior and are characterized by a disabling and progressive course. Anti-tumor necrosis factor (TNF)- $\alpha$  agents have drastically changed the therapeutic management of IBD. However, a significant proportion of patients does not have a primary response, some patients lose response overtime and/or experience side effects. Recently, anti-

adhesion molecules were investigated and showed efficacy with a good safety profile. Vedolizumab was recently approved for both Crohn's disease (CD) and ulcerative colitis (UC) and several other molecules are under evaluation in this field. Anti-adhesion molecules could represent a potential therapeutic option for future therapy in IBD. In this review we report the efficacy and safety of major anti-adhesion drugs in active IBD patients.

---

**Contacts:** Silvio Danese, Humanitas University IBD Center 20089 Rozzano, Milan Italy